Jefferies raises AstraZeneca target to 18,000p as analysts flip view on delayed cancer trial [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Broker upgrades odds on AVANZAR lung cancer trial after arguing repeated delays signal strong results in treatment arm Jefferies has lifted its price target on AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) , the FTSE 100 pharmaceutical company, from 15,000p to 18,000p, reiterating a 'buy' recommendation, arguing that the drugmaker is better positioned for long-term growth than the market appreciates. The broker's analysts have reversed their cautious stance on AVANZAR, a phase III clinical trial testing AZ's cancer drug Datroway (datopotamab deruxtecan) combined with immunotherapy Imfinzi and chemotherapy in patients with advanced non-small cell lung cancer (NSCLC). AVANZAR has been delayed twice and is now expected to report results in the second half of 2026. Rather than treating those delays as a warning sign, Jefferies argues they likely reflect better-than-expected survival rates in the patients receiving AstraZeneca's experimental combination therapy. The control arm in the
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck Trials, Tempus AI Deal And Leadership Shifts Shape Valuation Story [Yahoo! Finance]Yahoo! Finance
- Akeso Deepens Cadonilimab Story With Survival Data And Global GBM Trial [Yahoo! Finance]Yahoo! Finance
- Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Evaxion announces business update and full year 2025 financial results [Yahoo! Finance]Yahoo! Finance
- Assessing Merck (MRK) Valuation As Recent Share Price Strength Meets Conflicting Fair Value Views [Yahoo! Finance]Yahoo! Finance
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- 2/13/26 - Form 144/A
- MRK's page on the SEC website